Team2020-08-11T15:12:40-04:00
Page-TitleTEAM

VIRPAX Pharmaceuticals specializes in developing new drug delivery systems across various indications in order to increase compliance and maximize the ability to achieve full therapeutic efficacy.

What we do is important, but how we do it is just as important. As we drive our business forward, we must not lose sight of our fundamental commitment to doing business the right way. I expect people at all levels to always do the right thing, not just the easy thing – and to be motivated, empowered and supported in doing so.

Only by living up to our core values, wherever VIRPAX Pharmaceuticals Inc. has a presence or an impact, can we maintain the trust of our stakeholders and broader society that is so vital to our reputation and license to do business.

The VIRPAX Pharmaceuticals Inc. Code of Ethics & Business Conduct (the ”Code”) is our guide to understanding how our high level values are to be translated into consistent actions worldwide. It provides guidance about what is expected of each of us as we work to achieve our business goals. I expect you to study it closely and to live by its principles in your day-to-day business activities.

We are all responsible for making sure that nothing, including the need to meet objectives, direct orders from a more senior employee, or pressure from colleagues, ever compromises our commitment to honesty and integrity.

Compliance with this Code is mandatory for all VIRPAX Pharmaceuticals Inc. employees and consultants worldwide. It provides the framework for the application of consistent standards of responsible behavior that will ensure that VIRPAX Pharmaceuticals Inc. is an organization that is valued and respected by society and for which we are all proud to work.

ANTHONY P. MACK
CEO of VIRPAX Pharmaceuticals

OUR CORPORATE GOVERNANCE

We are dedicated to helping people manage pain in an ethical and responsible way. We have strong policies in place that help us get there.

READ MORE
SubheadEXECUTIVE LEADERSHIP
ANTHONY P. MACK, MBA2020-02-23T14:42:10-05:00

Chairman + CEO

Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Prior to founding VIRPAX in 2016, Mr. Mack founded SCILEX Pharmaceuticals and served as President and CEO until ZTlido was approved in February 2018. Mr. Mack founded his first pharmaceutical company ProSolus Pharmaceuticals in 2009, where he served as President before selling the company to Mission Pharmacal in 2015. Mr. Mack has held high-level management positions with Purdue Pharma, Endo Pharmaceuticals, Novartis, and EKR Therapeutics. He has led training, marketing, and commercial distribution for billion-dollar pain management products and has forged key strategic alliances. Mr. Mack has served as Founder, Director, and Executive Officer of both ProSolus Pharmaceuticals Inc. and SCILEX Pharmaceuticals. After SCILEX’s lead product, ZTlido, was approved for commercialization by the FDA, SCILEX was sold to a publicly traded company. Mr. Mack also founded and serves as Director of IACTA Pharmaceuticals Inc. By serving on executive boards, Mr. Mack has utilized his skills and experience to implement policies relating to corporate governance and overall business strategy. Mr. Mack holds an Executive MBA in Pharmaceutical and Healthcare Marketing from Saint Joseph’s University.

JEFFREY GUDIN, MD2020-02-23T14:42:14-05:00

EVP, Chief Medical Officer

Jeffrey Gudin, MD, was Director of Pain Management and Palliative Care at Englewood Hospital and Medical Center in New Jersey for almost 20 years. He is a Clinical Associate Professor in Anesthesiology at the Rutgers New Jersey Medical School.  Dr. Gudin is Board Certified in Pain Medicine, Anesthesiology, Addiction Medicine and Hospice and Palliative Medicine. He is an active speaker in the field of pain management. His clinical and research focus includes pain management, opioid abuse and potential solutions, and increasing clinician awareness of pain assessment and risk management. Dr. Gudin completed a residency in anesthesiology at Yale University School of Medicine, in New Haven, Connecticut. He continued his training with an extended postdoctoral fellowship in pain medicine at the Yale Center for Pain Management, where he was actively involved in research and teaching.

GERALD W. BRUCE2020-02-23T14:42:24-05:00

Gerald W. Bruce has spent over 30 years, including 20 years in senior leadership roles, in the Pharmaceutical and Medical Nutrition industry. He started his career at Johnson and Johnson where he was an award-winning sales representative and held leadership positions of increasing responsibility in sales and marketing ending with his role as Group Product Director of Analgesics. He then served as Vice President of Sales at Bristol-Myers Squibb where he led the Cardiovascular and Metabolic sales force responsible for over $1.2 Billion in sales. He later served as Vice President of Managed Markets where he led the team responsible for the development and implementation of the reimbursement strategy for the Bristol-Myers Squibb $7 billion US portfolio. Mr. Bruce went on to become the Senior Vice President of Commercial Operations at NitroMed where he was responsible for building the commercial strategy and led the team responsible for the development and implementation of the commercial plan for the start-up company’s first product for the treatment of Heart Failure. He also spent close to ten years in the Medical Nutrition industry where he was Vice President of Sales for Nutricia North America, Danone Medical Nutrition Division. Mr. Bruce currently serves on the Board of Trustees for Lincoln University and is a Board member for the National Sales Network. He received his bachelor’s degree in Business Administration from Lincoln University and a master’s degree in Leadership from the McDonough School of Business at Georgetown University.

CHRISTOPHER M. CHIPMAN, CPA2020-05-01T09:53:15-04:00

Chief Financial Officer

Christopher M. Chipman has been a managing member of Chipman & Chipman, LLC, since November 2000, a consulting firm that assists public companies with the preparation of periodic reports required to be filed with the Securities and Exchange Commission and compliance with Section 404 of the Sarbanes Oxley Act of 2002. The firm also provides outsourced financial resources to clients assisting in financial reporting, forecasting and accounting services for a variety of clients including pharmaceutical, agriculture and construction industries. Mr. Chipman is a CPA and was Chief Financial Officer and Secretary of Capital Gold Corporation from 2006 to June 2011. Capital Gold Corporation was a publicly-held gold production and exploration company, until its acquisition by AuRico Gold, Inc. (formerly, Gammon Gold). During his tenure, Capital Gold Corporation’s market capitalization increased from $40 million to $420 million. In addition, Capital Gold experienced an increase in proven and probable reserves in excess of 200%. Mr. Chipman successfully negotiated and facilitated the $420 million sale of Capital Gold Corporation to AuRico Gold representing a 67% premium over its market price to its shareholders. Additionally, Mr. Chipman oversaw the acquisition and integration into Capital Gold Corporation of Nayarit Gold in 2010, a $48 million Canadian advanced exploration company, including involvement in its valuation accounting and application of the purchase price allocation for the transaction.  From 1996 to 1998, he was a senior accountant with the accounting firm of Grant Thornton LLP; a Senior Financial Analyst for GlaxoSmithKline (1998-2000); and an Audit Examiner for Wachovia Corporation (1994-1996).  He received a B.A. in Economics from Ursinus College in 1994 and is a Certified Public Accountant. He is a member of the American and Pennsylvania Institute of Certified Public Accountants.

OVER 100+ YEARS

OF COMBINED EXECUTIVE EXPERIENCE IN THE PHARMACEUTICAL INDUSTRY

SubheadBOARD MEMBERS
ANTHONY P. MACK, MBA2020-02-23T14:42:10-05:00

Chairman + CEO

Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Prior to founding VIRPAX in 2016, Mr. Mack founded SCILEX Pharmaceuticals and served as President and CEO until ZTlido was approved in February 2018. Mr. Mack founded his first pharmaceutical company ProSolus Pharmaceuticals in 2009, where he served as President before selling the company to Mission Pharmacal in 2015. Mr. Mack has held high-level management positions with Purdue Pharma, Endo Pharmaceuticals, Novartis, and EKR Therapeutics. He has led training, marketing, and commercial distribution for billion-dollar pain management products and has forged key strategic alliances. Mr. Mack has served as Founder, Director, and Executive Officer of both ProSolus Pharmaceuticals Inc. and SCILEX Pharmaceuticals. After SCILEX’s lead product, ZTlido, was approved for commercialization by the FDA, SCILEX was sold to a publicly traded company. Mr. Mack also founded and serves as Director of IACTA Pharmaceuticals Inc. By serving on executive boards, Mr. Mack has utilized his skills and experience to implement policies relating to corporate governance and overall business strategy. Mr. Mack holds an Executive MBA in Pharmaceutical and Healthcare Marketing from Saint Joseph’s University.

JEFFREY GUDIN, MD2020-02-23T14:42:14-05:00

EVP, Chief Medical Officer

Jeffrey Gudin, MD, was Director of Pain Management and Palliative Care at Englewood Hospital and Medical Center in New Jersey for almost 20 years. He is a Clinical Associate Professor in Anesthesiology at the Rutgers New Jersey Medical School.  Dr. Gudin is Board Certified in Pain Medicine, Anesthesiology, Addiction Medicine and Hospice and Palliative Medicine. He is an active speaker in the field of pain management. His clinical and research focus includes pain management, opioid abuse and potential solutions, and increasing clinician awareness of pain assessment and risk management. Dr. Gudin completed a residency in anesthesiology at Yale University School of Medicine, in New Haven, Connecticut. He continued his training with an extended postdoctoral fellowship in pain medicine at the Yale Center for Pain Management, where he was actively involved in research and teaching.

ERIC FLOYD, PhD2020-02-11T20:08:56-05:00

Dr. Eric Floyd currently serves as Chief Regulatory Officer at Neurogene Inc. He has nearly 21 years of regulatory experience within the pharmaceutical industry. Most recently, he was Senior Vice President, Regulatory Affairs, for Axovant Sciences.  He served as President of Compliance Services and Chief Scientific Officer at Dohmen Life Science Services, Inc., Senior Vice President, US Regulatory Affairs and Clinical Quality Compliance at Lundbeck Inc., Global Vice President of Regulatory Affairs at Hospira, Vice President of Worldwide Regulatory Affairs and Quality Assurance at Cephalon and VP and Global Head of Respiratory, Dermatology, and Tropical Medicines Drug Regulatory Affairs at Novartis and held senior leadership roles at Bristol Myers Squibb, Aventis and Merck Research Laboratories. Dr. Floyd received a Ph.D. in Neurophysiology from Meharry Medical College, Nashville, an executive MBA from St. Joseph’s University, Philadelphia, an MS from Tennessee State University, a BS from the University of Illinois and has served as an Assistant Professor at Harvard University School of Medicine. Dr. Floyd served as an outside director on the Board of Directors of SCILEX Pharmaceuticals Inc. from 2014 to 2016.

JERROLD SENDROW, CFP2020-02-11T20:09:17-05:00

Mr. Jerrold Sendrow has been a Certified Financial Planner since 1986, and maintains a moderate practice. Mr. Sendrow also served as an outside Director on the Board of Directors of SCILEX Pharmaceuticals Inc. from 2014 to 2016. In addition, up through 2014, Mr. Sendrow has more than 35 years of experience as Chief Financial Officer and Director in companies with revenues in excess of $500 million. Jerry has led these companies through start-up, survival, turnaround and growth modes. Prior to that, Mr. Sendrow was an accountant in the audit departments of Touche Ross & Co. and Peat Marwick Mitchell & Co after returning from military service of two tours in the Vietnam conflict. Mr. Sendrow holds business degrees from Bernard Baruch College of the City University of New York and Adelphi University.

THANI JAMBULINGAM, PhD2020-02-11T20:09:39-05:00

Dr. Thani Jambulingam is a Pfizer Fellow and Professor in the Department of Pharmaceutical and Healthcare Marketing at St Joseph’s University, Erivan K. Haub School of Business, in Philadelphia, Pennsylvania, USA. He teaches in the executive MBA program for biopharmaceutical, medical device and physician executives. Dr. Jambulingam served as the chair of the department for 8 years. He is trained at Harvard in case method for teaching. Dr. Jambulingam’s research interests are in pharmaceutical and healthcare strategy, and innovation and published in marketing and management journals. Dr. Jambulingam has also served as a consultant and facilitated training sessions in innovation and strategy for senior leadership and/or brand teams within several small, mid and large pharma and healthcare firms including Alkermes, Abbott, Astra Zeneca, Lancaster General, Merck, Novo Nordisk, Pfizer, Solvay and Procter & Gamble. During his sabbatical, he joined Pfizer with the Prevenar Global Commercial Team contributing to development of Prevenar franchise positioning, healthy aging platform development, vaccine business strategy for emerging markets, pediatric expanded age strategy (life cycle management) and conducted strategy session for executive leadership within the specialty care division of Pfizer. Dr. Jambulingam is a pharmacist and obtained his Ph.D. from University of Wisconsin-Madison.

GARY S. JACOB, PhD2020-04-24T10:37:40-04:00

Director + Member, Science and Technology Committee

Dr. Jacob has over 35 years of extensive experience in the pharmaceutical and biotechnology industries across multiple disciplines, including research and development, operations, business development, capital financing activities and senior management expertise. He is the Co-Founder and former CEO and Chairman of Synergy Pharmaceuticals and has developed broad and influential contacts throughout the biopharmaceutical, financial, banking and investor communities.  He served as Chairman, Chief Executive Officer and a Director at Synergy Pharmaceuticals Inc. from July 2008 until October 2017 and is the co-inventor of the FDA-approved drug Trulance® which is currently marketed in the U.S. by Bausch Health, Inc. to treat functional GI disorders. Dr. Jacob is also the former CEO and Managing Director of Immuron Inc., an Australian biotechnology company dual-listed on the Australian ASX exchange and on NASDAQ.  Dr. Jacob currently is Chairman of the Board of Hepion Pharmaceuticals, Inc., a public NASDAQ listed company with a drug in clinical development to treat nonalcoholic steatohepatitis (NASH), and also is on the Board of Directors of Trovagene, Inc., a NASDAQ listed public oncology company. He served as Chief Executive Officer and Director of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013. Prior to his involvement with Callisto and Synergy, Dr. Jacob spent a number of years at Monsanto/G.D. Searle, where he was Director of Glycobiology and a Monsanto Science Fellow, specializing in the field of Glycobiology and drug discovery. Dr. Jacob holds over 15 patents and is the co-inventor of two FDA-approved pharmaceutical drugs. Dr. Jacob earned a B.S. in Chemistry cum laude from the University of Missouri – St. Louis and holds a Ph.D. in Biochemistry from the University of Wisconsin-Madison.

VANILA M. SINGH, MD, MACM2020-07-07T09:49:48-04:00

Director

Dr. Singh was the immediate past Chief Medical Officer in the US Department of Health and Human Services (“HHS”).  She served as the Chairperson of the highly regarded HHS Task Force in conjunction with the Department of Defense and the Veterans Administration. Dr. Singh is a clinical associate professor of Anesthesiology, Pain and Peri-operative Medicine at Stanford and is a teaching mentor at Walter Reed National Military Medical Center. She served in medical ethics as well as on scientific editorial boards, committees for the American Society of Regional Anesthesia, American Society of Interventional Pain Physicians, California Medical Association, and the Santa Clara County Medical Association. Dr. Singh, who is double board-certified in pain and anesthesiology, focuses her practice on regional anesthesia and peri-operative, subacute, and the development of chronic pain, with an appreciation for complimentary and traditional medicine approaches that emphasize an individualized patient-centered approach. She completed a masters in academic medicine as part of her professional development to further enhance leadership, educational curriculum development, and interdisciplinary work. Dr. Singh received her medical degree from George Washington University Medical School and her B.A. from U.C. Berkeley in Cell Biology/Economics.

CalloutEXPERIENCED COMMERCIAL MANAGEMENT TEAM WITHPROVEN TRACK RECORDSLAUNCHING AND MARKETING MULTIPLE PAIN PRODUCTS

LEARN HOW YOU CAN JOIN OUR TEAM AND TRANSFORM PAIN RELIEF

LEARN MORE
Go to Top